“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum, <i>et al</i>. <i>Eur Respir J</i> 2022; 59: 2002463.
European respiratory journal/The European respiratory journal